Spexis AG (XSWX:SPEX) Price-to-Tangible-Book : (As of Jun. 02, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Price-to-Tangible-Book?

As of today (2024-06-02), Spexis AG's share price is CHF0.0618. Spexis AG's Tangible Book per Share of Jun. 2023 for the quarter that ended in Jun. 2023 was CHF-0.14. Hence, Spexis AG's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Spexis AG's Price-to-Tangible-Book or its related term are showing as below:

During the past 10 years, Spexis AG's highest Price to Tangible Book Ratio was 52.50. The lowest was 1.38. And the median was 2.08.

XSWX:SPEX's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.79
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Spexis AG's share price is CHF0.0618. Spexis AG's Book Value per Sharefor the quarter that ended in Jun. 2023 was CHF0.33. Hence, Spexis AG's P/B Ratio of today is 0.19.

Spexis AG Price-to-Tangible-Book Historical Data

The historical data trend for Spexis AG's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Price-to-Tangible-Book Chart

Spexis AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Tangible-Book

Get a 7-Day Free Trial

1.70

1.65

52.50

Spexis AG Semi-Annual Data
	Dec13	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Price-to-Tangible-Book	Get a 7-Day Free Trial												-	52.50	-	-	-

Competitive Comparison of Spexis AG's Price-to-Tangible-Book

For the Biotechnology subindustry, Spexis AG's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spexis AG's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spexis AG's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Spexis AG's Price-to-Tangible-Book falls into.

Spexis AG Price-to-Tangible-Book Calculation

Spexis AG's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Jun. 2023 )
	=	0.0618	/	-0.137
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Spexis AG Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Spexis AG's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Spexis AG (XSWX:SPEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

SPEXz:UK

Address

Hegenheimermattweg 125, Allschwil, CHE, CH-4123

Website

https://www.polyphor.com

Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines